Loading
A phase 1/2 trial of Ipilimumab, Pembrolizumab, Nivolumab in cervical cancer and colorectal cancer, run by Neonc Technologies, Inc., now recruiting.
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis is a phase 1/2 interventional study registered as NCT06047379 by Neonc Technologies, Inc., with 134 participants planned, started 2023-11-01 and due to reach its primary completion in 2027-02-28. Interventions recorded: NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib. Conditions listed: Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Merkel cell carcinoma, Nivolumab, Head and neck squamous cell carcinoma, Melanoma.
Shares Ipilimumab, Nivolumab, Melanoma, Colorectal cancer.
Shares Ipilimumab, Paclitaxel / nab-paclitaxel, Nivolumab, Carboplatin.
Shares Ipilimumab, Nivolumab, Pembrolizumab.
Shares Merkel cell carcinoma, Ipilimumab, Nivolumab, Cervical cancer.
Shares Regorafenib, Ipilimumab, Nivolumab, Pembrolizumab.
Shares Ipilimumab, Nivolumab, Melanoma.
Shares Ipilimumab, Nivolumab, Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/